AC Immune Initiates Final Cohort in Alzheimer's Trial, Secures $12M Takeda Milestone
Summary
AC Immune SA announced the initiation of the final cohort in its Phase 1b/2 ABATE trial for ACI-24, an Alzheimer's treatment, triggering a $12 million milestone payment from Takeda.
Key Events
-
Clinical Trial Advancement
AC Immune initiated the final Cohort AD4 in its Phase 1b/2 ABATE trial for ACI-24, an anti-Abeta active immunotherapy for Alzheimer's disease.
-
Milestone Payment Received
The initiation of Cohort AD4 triggered a $12 million milestone payment from Takeda, under their exclusive option and license agreement.
-
Future Data Readout
Data from the earlier Cohorts AD1, AD2, and AD3 after 12 months of treatment are expected in Q2 2026.
Analysis
This filing details significant progress in AC Immune's lead Alzheimer's drug candidate, ACI-24, by advancing to the final cohort of its Phase 1b/2 ABATE trial. The associated $12 million milestone payment from Takeda provides non-dilutive capital and underscores the value of their partnership. This clinical advancement, coupled with the financial inflow, is a strong positive signal for the company's development pipeline and financial runway, especially with 12-month data from earlier cohorts expected soon.
At the time of this filing, ACIU was trading at $3.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $298.2M. The 52-week trading range was $1.51 to $4.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.